ff Divi's has reiterated its sales guidance at 15-20% and 37-38% margins for FY16E. Any new launches or approvals will add incrementally to the growth. Revenues of Nutraceuticals are guided at Rs2.2bn in FY16E, implying traction ahead. ff DSN SEZ contributed Rs2bn in 1Q as capacity utilization scaled up at 90%+,...